To assess the Efficacy and tolerability of Bisoprolol in patients with newly diagnosed Stage I essential hypertension.

Efficacy and tolerability of Bisoprolol in patients with newly diagnosed Stage I essential hypertension.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2010/091/000632

Enrollment

2000

Registered

2010-06-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Bisoprolol: starting dose = 2.5 mg and the upper recommended limit is 10mg once a day Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1 Newly diagnosed JNC 7 Stage I essential hypertension 2 Patient advised CONCOR (Bisoprolol) 3 No other clinically significant co-morbidities

Exclusion criteria

Exclusion criteria: 1 Any contraindications to CONCOR 2 Uncontrolled diabetes (Any ongoing symptoms or complication related to Diabetes) 3 Females in childbearing age not willing to use a reliable mean of contraception 4 Confirmed diagnosis of any CVD except Hypertension

Design outcomes

Primary

Measure	Time frame
Percentage of patients achieving BP < 140/ 90 mm HgTimepoint: At the end of 12 weeks(responder).	—

Secondary

Measure	Time frame
(1) Average reduction in systolic and diastolic BP. (2) Average time to reach target BP (in responders). (3) Average dose required to control (in responders). (4) Average reduction in Heart Rate. (5) Assessment of compliance at 12 weeks (pill count). (6) Blood Glucose parameters. (7) Renal parameter statusTimepoint: At the end of 12 weeks(responder).	—

Countries

India

Contacts

Public ContactDr. Amit Garg

Head- Medical services

amit.garg@merck.co.in02266609044

Outcome results